Telik telik.com


Public list: Pharma Startups (4732) Cancer Therapeutics (1137)

Telik, of Palo Alto, CA is a biopharmaceutical company working to discover, develop and commercialize small molecule drugs to treat serious diseases. The company's most advanced drug development candidate is TELCYTA (TLK286), a tumor-activated small molecule product candidate that is in Phase 3 registration trials in advanced ovarian and non-small cell lung cancer. Telik's product candidates were discovered using its proprietary drug discovery technology, TRAP, which enables the rapid and effici...Show all

Telik, of Palo Alto, CA is a biopharmaceutical company working to discover, develop and commercialize small molecule drugs to treat serious diseases. The company's most advanced drug development candidate is TELCYTA (TLK286), a tumor-activated small ...Show all

Company (IPO / Went public)

Phone: 650-845-7700

Fax:

3165 Porter Drive

Palo Alto, 94304
California, United States

Latest News

See more competitors data Competitors
Total Funding Date of Last Funding
Telik $48.7M Aug 12, 2000
See all 23 competitors

Web Traffic

Rank

Show (-10)

Engagement (PVPU)

Show (+1%)

Domain Authority Score
Show
Page Views Per Million (PVPM)
Show
Reach Per Million
Show

SEO Statistics

Domain Authority Score Show
Page Authority Score Show
No. External Links Show
No. Links Show

Web Traffic Statistics - Growth

Per Week Per Month Per 6 Months Per Year
Rank Login to see details
Page Views Per Million Login to see details
Page Views Per User Login to see details
Reach Per Million Login to see details

Related Telik Jobs

jobs by Indeed job
						search

Investors

Investor Investor Type Location Participating Rounds
See all 4 investors
There is no Board of Directors data available for this company. Please select another tab.

Competitors

Company Status Description Investors

Innoviva

Brisbane, California, United States
IPO / Went publicInnoviva, formerly known as Theravance, is focused on bringing compelling new medicines to patients in areas of unmet need by leveraging its significant expertise in the development, commercialization and financial management of bio-pharmaceuticals. Innoviva's portfolio is anchored by the respiratory assets partnered with Glaxo Group Limited (GSK), including RELVAR/BREO ELLIPTA and ANORO ELLIPTA, which were jointly developed by Innoviva and GSK. Under the agreement with GSK, Innoviva is eligible...Show allLogin to see details

Allos Therapeutics

Westminster, Colorado, United States
AcquiredAllos Therapeutics is a biopharmaceutical company focused on developing and commercializing small molecule drugs for the treatment of cancer. The Company's lead product candidate, pralatrexate (PDX) is a novel antifolate currently under evaluation in a pivotal Phase 2 (PROPEL) trial in patients with relapsed or refractory peripheral T-cell lymphoma. The PROPEL trial is being conducted under an agreement reached with the U.S. Food and Drug Administration under its special protocol assessment, or ...Show allLogin to see details
See all 23 competitors